Jefferies Adjusts Price Target on Moderna to $215
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
Stocks · News reference
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
Autozi Internet Technology (Global) Ltd. completed an initial closing of $12.75 million in senior secured convertible notes, with potential for up to $30 million total. The company plans to use proceeds for targeted M&A in auto parts supply chain, cross-border platform development, and R&D investments. The notes bear 9.25% annual interest and are convertible at $0.5232 per share with a November 2028 maturity date.
Anthropic is set to go public on November 19, 2026, at a $1.33 trillion valuation with a proposed IPO price of $70-$78 per share. While the company shows explosive revenue growth (12-fold increase to $17B in Q3), its 38x price-to-sales valuation is expensive. Historical data shows the 10 largest U.S. IPOs since 2006 declined an average of 32% from their IPO price within the first year, suggesting investors should wait for better entry points rather than buying at the IPO.
Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Ultragenyx Pharmaceutical Inc. while adjusting the price target downward from $35 to $24.
At the UBS Global Biopharma Conference, Ultragenyx management provided a financial outlook targeting full-year profitability in 2027 and outlined key budget constraints for R&D and SG&A expenses.